Categories AlphaGraphs, Earnings, LATEST

Delta Air Lines’ stock gets a boost after Q3 earnings beat estimates

Delta Air Lines (DAL) topped analysts’ expectations on earnings for the third quarter of 2018 but revenues slightly missed the mark. The stock rose 3.3% in premarket hours.

The airline reported total operating revenue of $11.9 billion, an increase of 8% from the same period last year. Adjusted operating revenue also grew 8%, driven by improvements in the business, including an increase of around 20% in premium product ticket revenues and double-digit percentage increases in cargo, loyalty and maintenance, repair and overhaul revenue.

Delta Air Lines third quarter 2018 Earnings Infographic
Delta Air Lines Q3 2018 Earnings Infographic

On a GAAP basis, net income improved 13% to $1.31 billion or $1.91 per share from the same period last year. Adjusted net income totaled $1.23 billion or $1.80 per share, reflecting a 16% increase in EPS that was driven by revenue momentum, tax reform benefits and a lower share count.

Total adjusted operating expenses rose $1 billion from last year, with more than half of the increase driven by higher fuel prices. Adjusted fuel expense rose 35% from last year while CASM-Ex remained flat.

Despite the higher expenses, the company saw revenue improvements across all its components. During all three months of the quarter, Delta saw growth in passenger traffic reach record levels which has helped push earnings growth.

Total unit revenues, excluding refinery sales, grew 4.3% fuelled by improvements in demand and yields. Revenue passenger miles increased 3.8% during the quarter while available seat miles increased 3.9%. Passenger load factor remained unchanged at 86.9%.

For the fourth quarter of 2018, Delta expects total revenue to grow around 8% and for total unit revenue, excluding refinery sales, to increase 3-5% year-over-year. EPS is expected to be $1.10 to $1.30.

Record traffic growth may help Delta fly past fuel woes in Q3

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top